Novartis and Bristol Myers Squibb helped the alpha radiotherapy developer complete a series A round after being incubated by MPM Capital.
US-based radiotherapeutics developer Aktis Oncology closed a $72m series A round yesterday that included pharmaceutical firms Novartis and Bristol Myers Squibb.
MPM Capital, the venture capital firm that incubated Aktis, co-led the round with investment adviser EcoR1 Capital and life sciences investment firm Vida Ventures. It also featured The Column Group’s TCG Crossover unit and Octagon Capital.
Aktis is working on targeted radiopharmaceuticals intended to treat a range of solid tumour-based cancers. It is focusing on alpha radiotherapies, which have…
